StockData
Boston Scientific Corp logo

Boston Scientific Corp

BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3053% below fair value
$43.64+0.61 (+1.42%)

Close on Nov 18, 2026Market cap $63.24BP/E 17.7Yield –

Boston Scientific Trailing 12-Month (TTM) Adjusted EBITDA by Quarter

Trailing 12-Month (TTM) Adjusted EBITDA ($M) ($M)

Boston Scientific Trailing 12-Month (TTM) Adjusted EBITDA: $6,192M in Q3 2026, up 7.5% from a year earlier.

Latest, Q3 2026
6,192
Period ended Sep 30, 2026
Change on a year earlier
+7.5%
5,759 in Q3 2025
History
15 quarters
Since Q1 2023
Sources
15
Documents cited below

Where the Q3 2026 figure comes from

“Adjusted EBITDA $ 1,558 $ 1,540 $ 1,630 $ 1,464 $ 6,192”

Source: BSX FY2026Q3 Financial & Operational Highlights Presentation ↗

Reported in Quarterly FOH Appendix C.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Boston Scientific Trailing 12-Month (TTM) Adjusted EBITDA ($M), quarterly Q1 2023–Q3 2026 [Data set]. Compiled from Boston Scientific SEC filings and investor materials. https://stockdatahq.com/stocks/bsx/kpis/lev-ttm-adj-ebitda

See every metric in the Boston Scientific KPI table. Data updated Nov 4, 2026.

See a number that looks wrong?